Abstracts

bNAb ESCAPE HIV-ENV VARIANTS IN ORALLY SHIV-INFECTED, ART-TREATED INFANT MACAQUES

Background: Each year >150,000 children are newly infected with HIV, majority during breastfeeding. Early life infection forces adherence to life-long ART. Development of autologous virus neutralizing antibodies or broadly neutralizing antibody (bNAb) therapy has been associated with delay in viral rebound after analytical treatment interruption (ATI). However, viral variants that escape neutralization response limit the…

LONG-ACTING LENACAPAVIR IN A COMBINATION REGIMEN FOR TREATMENT-NAIVE PWH: WEEK 80

Background: Lenacapavir (LEN), a potent first-in-class long-acting HIV-1 capsid inhibitor, is in development for treatment and prevention of HIV-1. CALIBRATE is an ongoing Phase 2 open-label active-controlled study evaluating subcutaneous (SC) and oral LEN, in combination with other antiretrovirals, in people with HIV-1 (PWH) who are initiating treatment. At the Week 54 (W54) primary endpoint,…

HIV TIME-SPACE ALERTS AMONG PWID AND MSM IN THE UNITED STATES, 2018-2021

Background: HIV time-space (TS) cluster detection is routinely conducted by CDC and by state and local health departments to identify U.S. counties where diagnoses are elevated compared with historical levels. These analyses generate “alerts” for review that may indicate clusters or outbreaks needing response. Previously, national TS cluster detection primarily focused on persons who inject…